PHASE IB TRIAL OF IMO-2055 IN COMBINATION WITH 5-FU, CISPLATIN AND CETUXIMAB IN 1ST-LINE PTS WITH RECURRENT/METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (R/M SCCHN)

被引：0
|
作者：
Machiels, J. P. [1 ]
Kaminsky, M. C. [2 ]
Keller, U. [3 ]
Bruemmendorf, T. H. [4 ]
Goddemeier, T. [5 ]
Forssman, U. [6 ]
Delord, J. P. [7 ]
机构：
[1] Clin Univ St Luc, B-1200 Brussels, Belgium
[2] Ctr Alexis Vautrin, Dept Med Oncol, Nancy, France
[3] Tech Univ Munich, Med Klin 3, Munich, Germany
[4] Univ Klinikum Aachen, Aachen, Germany
[5] Merck KGaA, Global Clin Operat Global Biostat, Darmstadt, Germany
[6] Merck Serono SA, Global Clin Dev Unit Oncol, Geneva, Switzerland
[7] Ctr Claudius Regaud, Clin Resarch Unit, Toulouse, France
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：342 / 342
页数：1
相关论文
共 50 条
  • [41] Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Cohen, Roger B.
    Salas, Sebastien
    Even, Caroline
    Kotecki, Nuria
    Jimeno, Antonio
    Soulie, Anne-Marie
    Tirouvanziam-Martin, Anne
    Zerbib, Robert
    Andre, Pascale
    Boyer-Chammard, Agnes
    Fayette, Jerome
    CANCER RESEARCH, 2017, 77
  • [42] A phase I study of everolimus in combination with cetuximab and cisplatin as first-line therapy inrecurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Chung, Christine H.
    Wang, Hao
    Tsottles, Nancy
    Gourin, Christine Gail
    Agrawal, Nishant
    Molinolo, Alfredo
    Gutkind, Silvio
    Forastiere, Arlene A.
    Marur, Shanthi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [43] Phase II study of dasatinib in combination with cetuximab in recurrent/metastatic head and neck squamous cell carcinoma
    Stabile, Laura P.
    Egloff, Ann Marie
    Zhou, Pei
    Gooding, William E.
    Grandis, Jennifer R.
    Bauman, Julie E.
    CANCER RESEARCH, 2016, 76
  • [44] A phase 2 study of tarloxotinib bromide (TRLX) in patients (Pts) with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).
    Rischin, Danny
    Boyer, Michael J.
    Brzezniak, Christina E.
    Colevas, A. Dimitrios
    Doebele, Robert Charles
    Gilbert, Jill
    Gitlitz, Barbara
    Khan, Saad A.
    Mehra, Ranee
    Seiwert, Tanguy Y.
    Kroll, Stew
    Pearce, Tillman E.
    Liu, Stephen V.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Systemic Chemotherapy with Cisplatin Plus 5-FU (PF) for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN): Efficacy and Safety of a Lower Dose of PF (80/800) at a Single Institution in Japan
    Kiyota, Naomi
    Tahara, Makoto
    Kadowaki, Shigenori
    Fuse, Nozomu
    Doi, Toshihiko
    Minami, Hironobu
    Ohtsu, Atsushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2009, 39 (04) : 225 - 230
  • [46] Phase II trial of cetuximab (C) and bevacizumab (B) in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN): Final results.
    Argiris, A.
    Kotsakis, A. P.
    Kim, S.
    Worden, F. P.
    Savvides, P.
    Gibson, M. K.
    Blumenschein, G. R.
    Chen, H. X.
    Grandis, J. R.
    Kies, M. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and, neck (SCCHN) refractory to first-line platinum-based therapies.
    Vermorken, JB
    Bourhis, J
    Trigo, J
    Kies, M
    Leon, X
    Mueser, M
    Amellal, N
    Schueler, A
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 501S - 501S
  • [48] A RANDOMIZED TRIAL OF CISPLATIN (CACP) + 5-FLUOROURACIL (5-FU) INFUSION AND CACP + 5-FU BOLUS FOR RECURRENT AND ADVANCED SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    KISH, JA
    ENSLEY, JF
    JACOBS, J
    WEAVER, A
    CUMMINGS, G
    ALSARRAF, M
    CANCER, 1985, 56 (12) : 2740 - 2744
  • [49] Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial
    Keil, Felix
    Hartl, Maximilian
    Altorjai, Gabriela
    Berghold, Andrea
    Riedl, Regina
    Pecherstorfer, Martin
    Mayrbaeurl, Beate
    De Vries, Alexander
    Schuster, Judith
    Hackl, Jutta
    Fuereder, Thorsten
    Melchardt, Thomas
    Burian, Martin
    Greil, Richard
    EUROPEAN JOURNAL OF CANCER, 2021, 151 : 201 - 210
  • [50] Phase 1 and Pharmacokinetic Study of Everolimus in Combination With Cetuximab and Carboplatin for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
    Saba, Nabil F.
    Hurwitz, Selwyn J.
    Magliocca, Kelly
    Kim, Sungjin
    Owonikoko, Taofeek K.
    Harvey, Donald
    Ramalingam, Suresh S.
    Chen, Zhengjia
    Rogerio, Jackie
    Mendel, Jennifer
    Kono, Scott A.
    Lewis, Colleen
    Chen, Amy Y.
    Higgins, Kristin
    El-Deiry, Mark
    Wadsworth, Trad
    Beitler, Jonathan J.
    Shin, Dong M.
    Sun, Shi-Yong
    Khuri, Fadlo R.
    CANCER, 2014, 120 (24) : 3940 - 3951
12345